Breaking News

ILiAD Selects Emmes Group to Conduct Phase III Studies of Pertussis Vaccine Candidate

Could significantly reduce the transmissibility and incidence of B. pertussis, particularly in vulnerable populations.

Author Image

By: Charlie Sternberg

Associate Editor

ILiAD Biotechnologies LLC, a late-stage biotech development company dedicated to the prevention of disease caused by Bordetella pertussis, has selected Emmes Group, a global contract research and technology organization, to conduct upcoming Phase III studies of its lead pertussis vaccine candidate, BPZE1.   ILiAD selected Emmes Group for its expertise in vaccine development, agility in managing complex clinical trials, strong local market presence, and its integrated technology capabilities. E...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters